C2N Diagnostics

C2N Diagnostics is a specialty diagnostics company dedicated to advancing brain health through innovative diagnostic solutions. With a vision to bring Clarity Through Innovation®, C2N provides cutting-edge clinical laboratory services and high-resolution mass spectrometry-based biomarker tools. These solutions are designed to improve patient care through accurate diagnosis and treatment monitoring, enhance the quality and efficiency of clinical trials for neurodegenerative diseases, and support researchers in understanding disease mechanisms and identifying new treatment targets.

C2N’s assays have been utilized in over 150 Alzheimer’s disease and neurodegeneration research studies worldwide, including landmark trials involving disease-modifying therapies (DMTs) that are transforming Alzheimer’s treatment. The company collaborates with leading pharmaceutical and biotech companies, academic institutions, and organizations such as the National Institute on Aging and the Alzheimer’s Association. Additionally, C2N has established research and distribution partnerships with global labs, including Grupo Fleury, Healius, Mayo Clinic Laboratories, and Unilabs, expanding its impact on global public health.

With over 50,000 Precivity™-related biomarker measures reported in peer-reviewed publications, C2N continues to lead in the field of brain health diagnostics. The company’s commitment to innovation and collaboration drives its mission to improve patient outcomes, accelerate drug development, and advance scientific understanding of neurodegenerative diseases.